Clinical Trials Browser

Has results × Endometrial Neoplasms × mirvetuximab soravtansine × Clear all

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Endometrial Neoplasms